Maxime Dely: Anticoagulant Is an Invisible Yet Essential Ally of Therapeutic Apheresis
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
”Anticoagulant: the invisible yet essential ally of therapeutic apheresis
At first glance, one might think it’s normal saline.
Pearling drops, a steady flow, almost reassuring. And yet… what you’re seeing is far more than a simple solution.
It is an anticoagulant, a fundamental pillar of therapeutic apheresis procedures: ACD-A (Acid Citrate Dextrose – Solution A).
Its mission is clear and essential: to prevent blood from clotting in the extracorporeal circuit during apheresis.
Without it, safe blood processing would simply not be possible.
In practice, anticoagulation ratios can be adjusted depending on the procedure. But not all procedures are equal in terms of duration.
Plasma exchange or red cell exchange typically last 1 to 2 hours.
However, during hematopoietic stem cell collections or lymphocyte collections for CAR-T cell manufacturing, patients may remain connected to the machine for 3 to 6 hours, sometimes processing up to three mass of total blood volumes to achieve the required cell yield.
The specificity of ACD-A?
Citrate chelates calcium, which may lead to hypocalcemia: perioral tingling, metallic taste, chills, tremors… and potentially more severe symptoms if not anticipated.
This is why true expertise in apheresis is essential.
Optimizing a procedure means finding the right balance between collection efficiency, clinical safety, and patient comfort.
It requires close collaboration between nurses, physicians… and industry partners.
Because in apheresis, every single drop matters.”
Stay updated with Hemostasis Today.
-
Apr 14, 2026, 16:02EU List of Critical Medicines Webinar Recording Now Available – EHC
-
Apr 14, 2026, 15:54Omar Adwan: Patterns of Anemia
-
Apr 14, 2026, 15:43Webinar on Aplastic Anemia Clinical Case – ASH
-
Apr 14, 2026, 15:42Heghine Khachatryan: Endometriosis Is Not Only a Pain Disorder
-
Apr 14, 2026, 15:36Alisha Tuck: Navigating the First Trimester with Ultrasound and Anticoagulation Management
-
Apr 14, 2026, 15:26Tijjani Balas: The End of ‘Type O Negative’ Shortages? – A New Era in Blood Transfusion
-
Apr 14, 2026, 15:07Carlos Henrique Del Carlo: HFpEF Reimagined as an Adipose Tissue Driven Disease
-
Apr 14, 2026, 15:05Matteo Foschi: ASPERA-R Study Reveals Competing Causes Of Breakthrough Stroke On Anticoagulation
-
Apr 14, 2026, 14:48Samwel Mikaye: From Virchow’s Triad to Prevention of PE in Patients with DVT